Superworth

Protalix BioTherapeutics price to sales ratio PLX

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026
2.5×
10-year median
2.1×
Against its 10-year history
62nd
percentile: 0 is its lowest day, 100 its highest
10-year range
0.6× to 18.4×
Peer median
1.7×

Protalix BioTherapeutics' price to sales ratio is 2.5× as of Oct 23, 2026.

That is above its ten-year median of 2.1×, close to the middle of its last ten years.

Over that time it ranged from 0.6× in Oct 2019 to 18.4× in Mar 2017.

The median for 10 healthcare stocks of a similar size is 1.7×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far2.5×2.1×4.0×
20252.4×1.9×4.4×
20243.0×1.3×3.0×
20232.0×1.5×5.2×
20221.5×0.7×1.8×
20210.8×0.8×4.5×
20202.0×0.6×2.2×
20190.9×0.6×8.4×
20184.5×3.0×6.9×
20174.9×4.1×18.4×
20165.5×5.4×6.5×
20157.0×5.7×18.0×
201412.4×12.4×52.2×
201338.7×13.3×45.5×
201213.5×12.7×76.5×

Against its peers

Companies in Healthcare nearest Protalix BioTherapeutics' size, closest first, today.

CompanyPrice to sales ratio
PLXProtalix BioTherapeutics2.5×
PDEXPro DEX2.6×
NATRNatures Sunshine Products0.4×
ELMDElectromed3.0×
UTMDUtah Medical Products6.5×
INFUInfuSystem1.9×
VMDViemed Healthcare1.2×
EMBCEmbecta0.4×
KEQUKewaunee Scientific0.3×
ICCCImmucell3.0×
ARVNArvinas1.5×
Peer median1.7×

Where Protalix BioTherapeutics ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Protalix BioTherapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.